Caterol 150 DPI Capsule
Indacaterol
150 mcg
Incepta Pharmaceuticals Ltd.
| Pack size | 30's Pack |
|---|---|
| Unite Price | 35.00 BDT |
Indications
Caterol 150 DPI Capsule is used for:
Indacaterol Maleate is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with, chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Adult Dose
Inhalation
Maintenance therapy in chronic obstructive pulmonary disease
Adult: As inhal cap: Inhale 75-150 mcg once daily using inhaler.
Max: 300 mcg once daily.
Hepatic impairment
No dose adjustment is required for patients with mild and moderate hepatic impairment.
There are no data available for use of Onbrez Breezhaler in patients with severe hepatic impairment.
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment
No dose adjustment is required for patients with renal impairment.
Administration
Contra Indications
All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication. Indacaterol is not indicated for the treatment of asthma. Indacaterol is contraindicated in patients with a history of hypersensitivity to indacaterol or to any of the ingredients.
Precautions
Not intended for treatment of asthma and acute deterioration of COPD. Patient w/ acutely deteriorating COPD, thyrotoxicosis, seizure disorders, DM, hypokalaemia, CV disorders esp coronary insufficiency, cardiac arrhythmias or HTN. Pregnancy and lactation.
Lactation: Unknown whether distributed in human breast milk; use caution
Pregnancy-Lactation
Pregnancy Category: C
Beta-agonists are known to inhibit uterine contractility
Lactation: Unknown whether distributed in human breast milk; use caution
Interactions
Potentiated adverse effects w/ other sympathomimetic agents; possible hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics. Other long-acting beta2-adrenergic agonists or medicinal products containing long-acting beta2-adrenergic agonists. Inhibition of the key contributors of indacaterol clearance, CYP3A4 and P-gp.
Side Effects
Side effects of Indacaterol :
>10%
Post-inhalation cough (24% compared with 7% on placebo)
1-10%
Cough (6.5%), Nasopharyngitis (5.3%), Headache (5.1%), Nausea (2.4%), Oropharyngeal pain (2.2%)
Potentially Fatal: Asthma-related deaths.
Mode of Action
Indacaterol is a long acting β2-adrenergic agonist. It relaxes the bronchial smooth muscle by selective action on β2-receptor which acts locally in the lungs and w/ little effect on heart rate.
Note
Caterol 150 150 mcg DPI Capsule generic name is Indacaterol. Caterol 150 150 mcg DPI Capsule is manufactured by Incepta Pharmaceuticals Ltd.Caterol 150 is availble in all over Bangladesh.
Mes BD drug index information on Caterol 150 DPI Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Indacaterol :
Dry powder inhalation capsule
Onbrez Breezhaler
150mg
Novartis (Bangladesh) Ltd.
Dry Powder Inhalation Capsule
Onbrez Breezhaler
300mg
Novartis (Bangladesh) Ltd.
Dry Powder Inhalation Capsule
Onriva
75mcg
Beximco Pharmaceuticals Ltd.
DPI Capsule
Caterol 75
75mcg
Incepta Pharmaceuticals Ltd.
Inhalation Capsule
Oxima 150 Acucap
150mcg
ACI Limited